Fecal Microbiota Transplantation Improves the Quality of Life in Patients with Inflammatory Bowel Disease

Table 1

Basic characteristics of patients.

Patients	Sex	Age	Diagnosis	Basic IBDQ/activity	Duration of disease; (year)	Concomitant medication	Route of FMT	BMI
A	Female	70	UC	104/6	10	Mesalazine	C	19.4
B	Female	59	UC	120/9	4	Mesalazine glucocorticoid	C	23.9
C	Male	40	CD	100/—	6	SASP	NJT	16.7
D	Male	16	CD	118/400	0.5	None	NJT	12
E	Female	48	UC	162/8	3	Mesalazine	C	24.2
F	Female	47	UC	100/4	6	Gentamicin	C	18.3
G	Male	24	CD	104/290	1	None	C	17.6
H	Male	26	UC	109/5	2	Mesalazine	C	20.8
I	Female	39	UC	155/4	1.5	Gatifloxacin	C	22.3
J	Female	49	UC	142/8	10	Mesalazine	C	23.2
K	Female	70	UC	163/5	1	Norfloxacin	C	20
L	Male	36	UC	134/4	6	None	C	26.1
M	Male	41	UC	123/12	1	Mesalazine	C	22.8
N	Female	32	UC	146/5	5	Mesalazine	C	21.5

SASP: salicylazosulfapyridine; UC: Ulcerative colitis; CD: Crohn’s disease; C: colonoscope; NJT: nasojejunal tube.